** Hong Kong shares of vaccine producer CanSino Biologics Inc 6185.HK jump 7% to HK$32.20, their highest since Jan. 6, and on track for sixth straight session of gain
** Stock on track for the biggest one-day pct gain since Nov. 11, 2024
** Shanghai-listed stock 688185.SS climbs 3.5% to 63.66 yuan, high since Dec. 31, 2024
** CanSino said China's National Medical Products Administration (NMPA) granted priority review status to the firm's new drug application (NDA) for its absorbed diphtheria, tetanus and acellular pertussis combined vaccine for infants below 2 years
** NMPA will prioritize resource allocation for the review of NDAs, included in the scope of priority review and approval - co
** Hong Kong's healthcare index .HSCIH rises 1.4%, Hang Seng Index .HSI surges 1.7%
** Hong Kong stock rose 33.8% last year, while Shanghai-listed shares fell 18.1%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.